Clinical trials


Select item(s)
Key Findings
No significant improvements were observed in clinical status (in terms of WHO 7-point ordinal scale) between different treatment groups (Lopinavir/Ritonavir, IFN-Ŗ-1a, Hydroxychloroquine) and control group patients on the 15th day and 29th day.
PMID
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
Among all treatment group patients, Lopinavir/ritonavir group patients experienced more serious adverse effects (52.8% in the lopinavir/ritonavir group vs. 38.5% in the control group; 54.2% in the lopinavir/ritonavir plus IFN-Ŗ-1a group vs. 38.5% in the control group). 44.1% of patients in the Hydroxychloroquine treated group had Serious adverse effects.
PMID
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
No significant reduction in viral load was observed from baseline to day 15 among different treatment group patients (Lopinavir/Ritonavir, IFN-Ŗ-1a, Hydroxychloroquine, and control group ).
PMID
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name-
Journal
Impact factor
Citation count
Date of publishing-
The case study is of a 66-year-old man who experienced acute colic perforation after being treated with tocilizumab and corticosteroids for his COVID-19 diagnosis.
PMID 32402416
Title Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case
Author(s) nameGonz√°lvez Guardiola P, D√≠ez Ares J√Ā, Peris Tom√°s N, Sebasti√°n Tom√°s JC, Navarro Mart√≠nez S.
Journal Cir Esp
Impact factor0.36
Citation count1
Date of publishing2021 Feb
Ivermectin-treated group patients had a lower mortality rate compared to the control group patients. Mortality also was lower in the subgroup of Ivermectin-treated patients with severe pulmonary involvement.
PMID 33065103
Title Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study
Author(s) nameRajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ.
Journal Chest
Impact factor7.22
Citation count19
Date of publishing2021 Jan
Compared to the placebo group patients, the fluvoxamine-treated group patients showed less serious adverse effects.
PMID 33180097
Title Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) nameLenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM.
Journal JAMA
Impact factor14.78
Citation count6
Date of publishing2020 Dec 8
No patients in the fluvoxamine-treated group had clinical deterioration, whereas 8.3% of patients in the placebo group showed clinical deterioration.
PMID 33180097
Title Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) nameLenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM.
Journal JAMA
Impact factor14.78
Citation count6
Date of publishing2020 Dec 8
Several common serious adverse effects were observed between two groups of patients (IFX-1 and control). In the IFX-1 group, 23 serious adverse effects occurred in 9 out of 15 patients. In the control group, 19 adverse effects occurred in 7 out of 15 patients.
PMID 33015643
Title Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Author(s) nameVlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D.
Journal Lancet Rheumatol
Impact factor<3years
Citation count8
Date of publishing2020 Dec
A significant increase in Aminotransferase levels was observed in patients treated with Tocilizumab (TCZ), compared to Anakinra (ANA) treated group patients.
PMID 32843231
Title High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) nameIglesias-Juli√°n E, L√≥pez-Veloso M, de-la-Torre-Ferrera N, Barraza-Vengoechea JC, Delgado-L√≥pez PD, Colazo-Burlato M, Ubeira-Iglesias M, Montero-Balad√≠a M, Lorenzo-Mart√≠n A, Minguito-de-la-Iglesia J, Garc√≠a-Mu√Īoz JP, Sanllorente-Sebasti√°n R, Vicente-Gonz√°lez B, Alem√°n-Alem√°n A, Buz√≥n-Mart√≠n L.
Journal J Autoimmun
Impact factor7.32
Citation count3
Date of publishing2020 Dec
HCQ did not significantly reduce the viral load in patients. No differences in the viral load reduction between the two groups of patients were observed (HCQ and control group).
PMID 33111169
Title No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19
Author(s) nameFaíco-Filho KS, Conte DD, de Souza Luna LK, Carvalho JMA, Perosa AHS, Bellei N.
Journal Braz J Microbiol
Impact factor1.67
Citation count2
Date of publishing2020 Dec
55.6% and 88.9% of patients showed positive outcomes when treated with Anakinra (ANK) and Tocilizumab (TCZ), respectively. Two patients who did not improve by TCZ drug treatment were treated successfully by ANK treatment. ANK is a potential alternative drug for treating patients who are not responding to TCZ.
PMID 32843231
Title High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) nameIglesias-Juli√°n E, L√≥pez-Veloso M, de-la-Torre-Ferrera N, Barraza-Vengoechea JC, Delgado-L√≥pez PD, Colazo-Burlato M, Ubeira-Iglesias M, Montero-Balad√≠a M, Lorenzo-Mart√≠n A, Minguito-de-la-Iglesia J, Garc√≠a-Mu√Īoz JP, Sanllorente-Sebasti√°n R, Vicente-Gonz√°lez B, Alem√°n-Alem√°n A, Buz√≥n-Mart√≠n L.
Journal J Autoimmun
Impact factor7.32
Citation count3
Date of publishing2020 Dec
Clinical outcomes in patients treated with IFX-1 (vilobelimab) showed a positive (but not significant) difference compared to the control group. The mortality by 28 days was 13% for the IFX-1 group and 27% for the control group. IFX-1 resulted in C5a inhibition and appeared to be safe and promising in treating severe COVID-19 patients.
PMID 33015643
Title Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Author(s) nameVlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D.
Journal Lancet Rheumatol
Impact factor<3years
Citation count8
Date of publishing2020 Dec
Patients treated with Anakinra within 36 hours after the onset of acute hypoxemic respiratory failure showed better improvement (without mechanical ventilation).
PMID 32602262
Title Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID19: A Case Series
Author(s) nameNavarro-Mill√°n I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK.
Journal Arthritis Rheumatol
Impact factor7.34
Citation count11
Date of publishing2020 Dec
Adverse effects were similar between two groups (Remdesivir and placebo) of patients. Serious adverse effects were reported in 131 patients in the Remdesivir group and 163 patients in the placebo group.
PMID 32445440
Title Remdesivir for the Treatment of Covid-19 Final Report
Author(s) nameBeigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members.
Journal N Engl J Med
Impact factor37.91
Citation count690
Date of publishing2020 Nov 5
Patients treated with the Remdesivir had better clinical improvement and less mortality than patients in the placebo group.
PMID 32445440
Title Remdesivir for the Treatment of Covid-19 Final Report
Author(s) nameBeigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members.
Journal N Engl J Med
Impact factor37.91
Citation count690
Date of publishing2020 Nov 5
16 out of 17 COVID-19 patients with profound B-cell lymphopenia showed an effective improvement (in clinical symptoms and biological parameters) when treated with the passive transfer of COVID-19-neutralizing antibodies through CPT.
PMID 32959052
Title Convalescent plasma therapy for B-celldepleted patients with protracted COVID-19
Author(s) nameHueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, Chatenoud L, Eshagh D, Szwebel TA, Martinot M, Camou F, Crickx E, Michel M, Mahevas M, Boutboul D, Azoulay E, Joseph A, Hermine O, Rouzaud C, Faguer S, Petua P, Pommeret F, Clerc S, Planquette B, Merabet F, London J, Zeller V, Ghez D, Veyer D, Ouedrani A, Gallian P, Pacanowski J, Mékinian A, Garnier M, Pirenne F, Tiberghien P, Lacombe K.
Journal Blood
Impact factor10.66
Citation count9
Date of publishing2020 Nov 12
This case study is of an 80-year-old SARS-CoV-2 female patient who underwent acetylcysteine treatment to counteract Remdesivir associated acute liver failure.
PMID 33006138
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) nameCarothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor3.17
Citation count1
Date of publishing2020 Nov
The patient treated with Remedesivir experienced acute liver failure which improved with the treatment of acetylcysteine
PMID 33006138
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) nameCarothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor3.17
Citation count1
Date of publishing2020 Nov
The patient treated with Remedesivir experienced acute liver failure which improved with the treatment of acetylcysteine
PMID 33006138
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) nameCarothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor3.17
Citation count1
Date of publishing2020 Nov
Compared to the HCQ alone or no treatment group patients, the combination-treated group patients (HCQ+ azithromycin) had a lower mortality rate.
PMID 32926573
Title Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19
Author(s) nameLauriola M, Pani A, Ippoliti G, Mortara A, Milighetti S, Mazen M, Perseghin G, Pastori D, Grosso P, Scaglione F.
Journal Clin Transl Sci
Impact factor3.75
Citation count5
Date of publishing2020 Nov
Compared to the control group patients (not-transfused), patients transfused within 72 hours of hospital admission had decreased mortality within 28 days. And a significant reduction in mortality was observed in patients transfused with high anti-RBD IgG titer COVID-19 convalescent plasma within 72 hours of admission.
PMID 32795424
Title Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality
Author(s) nameSalazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Eagar TN, Yi X, Zhao P, Rogers J, Shehabeldin A, Joseph D, Leveque C, Olsen RJ, Bernard DW, Gollihar J, Musser JM.
Journal Am J Pathol
Impact factor3.71
Citation count15
Date of publishing2020 Nov
A pregnant woman with severe COVID-19 was treated successfully with Tocilizumab and Remdesivir with better clinical improvement.
PMID 32618794
Title Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19)
Author(s) nameNaqvi M, Zakowski P, Glucksman L, Smithson S, Burwick RM.
Journal Obstet Gynecol
Impact factor3.78
Citation count5
Date of publishing2020 Nov
This case study involves a 68-year-old SARS-CoV-2 positive female patient with a medical history of coronary artery disease, was treated with Remedesivir. The patient experienced associated acute liver failure, which improved with the treatment of acetylcysteine.
PMID 33006138
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) nameCarothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor3.17
Citation count1
Date of publishing2020 Nov
SARS-CoV-2 Patients associated with Severe Bronchospasm were treated with Ipratropium bromide, adrenaline, and magnesium sulfate.
PMID 33173630
Title Decreased Mortality in Patients With Severe Bronchospasm Associated With SARS-CoV-2: An Alternative to Invasive Mechanical Ventilation
Author(s) nameSalazar R Sr, Hallo A, Vasquez S, Reinthaller S, Echeverria J.
Journal Cureus
Impact factorCant find
Citation count1
Date of publishing2020 Oct 6
The combined treatment of Remdesivir and convalescent plasma therapy created an effective virological response for an immunocompromised patient who was previously struggling to control the viremia.
PMID 33103195
Title Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19
Author(s) nameMalsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, L√ľtgehetmann M, Rosien U, Jasper D, Peine S, Hiller J, Haag F, Schmiedel S, Huber S, Jordan S, Addo MM, Schulze Zur Wiesch J.
Journal Clin Infect Dis
Impact factor7.71
Citation count2
Date of publishing2020 Oct 26